Author Question: Dr. Lewis is a neurologist. Today he is seeing a patient referred to him by Dr. Williams. Dr. Lewis ... (Read 202 times)

fnuegbu

  • Hero Member
  • *****
  • Posts: 539
Dr. Lewis is a neurologist. Today he is seeing a patient referred to him by Dr. Williams. Dr. Lewis will be providing a written report of his visit with this patient to Dr. Williams.What type of E/M code should be assigned for the visit and services of Dr. Lewis?
 A) new patient
  B) established patient
  C) preventive medicine visit
 D)consult

Question 2

An E/M code is assigned based on provider documentation in the office __________.
 A) superbill
  B) charge ticket
  C) record
 D)encounter form



jxjsniuniu

  • Sr. Member
  • ****
  • Posts: 343
Answer to Question 1

D

Answer to Question 2

C



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

People who have myopia, or nearsightedness, are not able to see objects at a distance but only up close. It occurs when the cornea is either curved too steeply, the eye is too long, or both. This condition is progressive and worsens with time. More than 100 million people in the United States are nearsighted, but only 20% of those are born with the condition. Diet, eye exercise, drug therapy, and corrective lenses can all help manage nearsightedness.

Did you know?

Patients should never assume they are being given the appropriate drugs. They should make sure they know which drugs are being prescribed, and always double-check that the drugs received match the prescription.

Did you know?

In inpatient settings, adverse drug events account for an estimated one in three of all hospital adverse events. They affect approximately 2 million hospital stays every year, and prolong hospital stays by between one and five days.

Did you know?

Women are two-thirds more likely than men to develop irritable bowel syndrome. This may be attributable to hormonal changes related to their menstrual cycles.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library